Ojemda (Tovorafenib) Patent Expiration, LOE Window & CMS Spending

Ojemda (Tovorafenib) by Day One Biopharmaceuticals: FDA Orange Book core substance LOE 2031-08-04 (last listed 2035-06-23), 0 AB generics, $20.2M 2024 CMS Part D & Medicaid spend, and $33,916 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorDay One Biopharmaceuticals
FDA Application & PathwayN217700 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-08-04
Last Listed Patent or Exclusivity Date2035-06-23
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$20.2M
2024 Medicare Part D Spend$705K
2024 Medicaid Spend$19.5M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($33,916 intro WAC)